cjc 1295 with/ipamorelin CJC-1295 + Ipamorelin Blend 10mg | Research Use Only CJC 1295 no DAC &

Frequency: 5x a week

Absolute contraindications include: Active malignancy of any kind (GH and IGF-1 are growth-promoting signals) Active diabetic retinopathy (IGF-1 may worsen retinal vascularity) Pregnancy or breastfeeding Known hypersensitivity to any component of the formulation Pituitary tumours or untreated hypothalamic disease Relative contraindications requiring careful evaluation include pre-existing insulin resistance, type 2 diabetes, uncontrolled cardiovascular disease, and sleep apnoea (GH elevation can worsen upper airway tone in susceptible individuals)

While its not FDA-approved for specific indications like diabetes or growth disorders, doctors have the authority to prescribe it off-label for legitimate therapeutic purposes including performance optimization and hormone replacement

Additionally, by engaging signaling pathways such as JAK/STAT, growth hormone may drive the transcription of genes involved in lipid mobilization, thereby further promoting lipolysis and potentially reducing visceral fat stores